By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Danish obesity drug giant Novo Nordisk is set ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

Novo Nordisk’s stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts’ forecasts.

COPENHAGEN, Feb 3 () - Wegovy maker Novo Nordisk warned on Tuesday that profits and sales could drop as much as 13% this year ...

The Danish drugmaker said adjusted sales should decline between 5% and 13% at constant exchange rates in 2026.

Novo Nordisk’s U.S.-traded shares slid 13% Tuesday after the drugmaker unexpectedly warned that its 2026 sales would decline more sharply than expected, as pricing pressure weighs on U.S. sales of its ...

Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs.

By Harshita Mary Varghese and Patrick Wingrove Jan 28 (Reuters) - Novo Nordisk spent nearly $500 million on U.S. advertising ...

Danish pharmaceutical giant Novo Nordisk said yesterday that it expects 2026 sales to slide by up to 13 per cent as prices ...

For full-year 2025, sales are projected at DKK 307.62B, up from DKK 290.4B in 2024, with Wegovy contributing DKK 78.28B and Ozempic DKK 124.87B. EPS is forecast at DKK 23.28, compared with DKK 22.63 ...

Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.